These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease. Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349 [TBL] [Abstract][Full Text] [Related]
12. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. Rahmat LT; Logan AC Drugs Today (Barc); 2018 May; 54(5):305-313. PubMed ID: 29911695 [TBL] [Abstract][Full Text] [Related]
13. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD. Olivieri A; Mancini G Cells; 2024 Sep; 13(18):. PubMed ID: 39329708 [TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
15. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint. Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140 [TBL] [Abstract][Full Text] [Related]
16. Novel developments in the prophylaxis and treatment of acute GVHD. Jamy O; Zeiser R; Chen YB Blood; 2023 Sep; 142(12):1037-1046. PubMed ID: 37471585 [TBL] [Abstract][Full Text] [Related]
17. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis. Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925 [TBL] [Abstract][Full Text] [Related]
18. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease. De Togni E; Cole O; Abboud R Front Immunol; 2024; 15():1304065. PubMed ID: 38380328 [TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481 [TBL] [Abstract][Full Text] [Related]
20. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]